Drug intelligence / Profile preview

cyclophosphamide + ipilimumab + nivolumab + pegylated liposomal doxorubicin

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

This is a combination therapy consisting of four components: cyclophosphamide (an alkylating agent), ipilimumab (a CTLA-4 inhibitor), nivolumab (a PD-1 inhibitor), and pegylated liposomal doxorubicin (an anthracycline chemotherapy agent). The pegylated liposomal doxorubicin component is enclosed in pegylated liposomes, which slows down removal of the medicine, allowing it to circulate in the blood for longer and reduces effects on healthy tissues and cells, making it less likely to cause certain side effects compared to standard doxorubicin.

Targets

TOP2A (DNA topoisomerase II)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)PDCD1 (Programmed cell death protein 1 receptor)DNA

Beyond the preview

Go deeper on cyclophosphamide + ipilimumab + nivolumab + pegylated liposomal doxorubicin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cyclophosphamide + ipilimumab + nivolumab + pegylated liposomal doxorubicin.

Explore the full profile